Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among

Published
27 July 2015
By
Gus Cairns
Gay youth PrEP study finds good retention and reasonable adherence

A US study of pre-exposure prophylaxis (PrEP) in 200 young gay and bisexual men aged 18-22 found reasonable levels of adherence. Adherence was highest in those

Published
24 July 2015
By
Gus Cairns
Intermittent PrEP may be a robust strategy for anal sex – vaginal much less certain

The pharmacodynamics (drug absorption and elimination rates) of the two drugs that comprise Truvada may favour the efficacy of intermittent pre-exposure prophylaxis (PrEP) more than previously thought, at

Published
22 July 2015
By
Gus Cairns
The pros and cons of PrEP: trial volunteers recount their experience of the ADAPT study

The reasons whether or not people come forward for pre-exposure prophylaxis (PrEP) or take it once prescribed are likely to be very mixed, and dependent as much

Published
22 July 2015
By
Gus Cairns
Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing

For some people in some settings, less frequent pre-exposure prophylaxis (PrEP) regimens with doses linked to sexual activity are feasible, with high numbers of sexual acts protected

Published
21 July 2015
By
Roger Pebody
Vancouver Consensus Statement calls for early access to treatment and PrEP worldwide

Leading figures in the HIV response have endorsed a call for immediate access to antiretroviral therapy for all people upon diagnosis with HIV, on the opening day

Published
20 July 2015
By
Keith Alcorn
Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.

Published
19 July 2015
From
AVAC
Oral pre-exposure prophylaxis – questions and answers

Implementing PrEP poses new challenges in planning, managing and funding combination prevention.

Published
17 July 2015
From
UNAIDS
Study sheds light on how tenofovir is processed in different body tissues

The findings have implications for the effectiveness of tenofovir for pre-exposure prophylaxis (PrEP). Genetic variation might explain some cases of PrEP failure.

Published
17 July 2015
From
HIVandHepatitis.com
San Francisco Sees Declines in New HIV Infections and Deaths of People with HIV

Experts agree that the decline in new infections is due to a combination of factors including widespread testing, early antiretroviral therapy (ART), and possibly pre-exposure prophylaxis -- although PrEP is probably too recent to have had a substantial effect yet.

Published
17 July 2015
From
HIVandHepatitis.com
← First12345...60Next →

Filter by country